Does the patient have a suicidal tendency after receiving the "Weight Loss Needle" injection? Psychiatrists Reveal Psychopharmaceuticals for Weight Loss Patients | Report | Psychiatry
Novo Nordisk's GLP-1 drug has recently reported three cases in Iceland where patients have a tendency to commit suicide or self harm after taking the medication. In this regard, the European Drug Administration said that it was investigating Ozempic, a diabetes drug containing Smeglutide, and Saxenda, another weight loss drug containing Lilalutide. Novo Nordisk responded that the company takes all reports related to adverse events very seriously. In a statement, Novo Nordisk stated that its own safety monitoring has not found a "causal relationship" between patients' self harm tendencies and medication so far. The European Medicines Agency has stated that it will investigate drugs containing smeglutide and liraglutide. Novo Nordisk's other approved smeglutide product, Wegovy, also contains smeglutide components in the United States. The agency also stated that it is considering expanding the investigation to all GLP-1 drugs. Previously, the European Medicines Agency also stated that it would investigate whether GLP-1 drug is associated with thyroid cancer. At present, "suicidal thoughts" are not listed as a side effect in the EU product information for both Ozempic and Saxenda drugs. However, in the United States, Wegovy's prescription for weight loss suggests monitoring patients' suicidal thoughts or behaviors. According to the data from the US FDA Adverse Event Reporting System, since 2018, 60 suicidal tendencies have been reported in patients using Smegglutide; Since 2010, FAERS has received at least 70 such reports from users of liraglutide or their healthcare providers. However, the FDA emphasizes that the information in these reports has not been validated, and therefore cannot prove a direct causal relationship between drug use and suicidal thoughts. In addition, in the clinical trials of Ozempic and Saxenda, Novo Nordisk excluded individuals with a history of mental illness or recent suicidal behavior. The mechanism of action of GLP-1 drugs includes inhibiting the appetite center and producing a sense of anorexia; Inhibiting gastric emptying and producing a feeling of fullness can achieve weight loss by reducing food intake. Common adverse reactions include nausea, vomiting, and anorexia. There is currently no in-depth research on the side effects of using such drugs on the human brain. But psychiatrists have pointed out a potential association between depression and weight loss. Chen Jun, chief physician of the Shanghai Mental Health Center, told First Financial reporters, "A considerable portion of people who lose weight are motivated by excessive attention to their physical appearance, which may be caused by anxiety and depression." He also talked about a mental illness called "eating disorder", which includes anorexia, gluttony, and binge eating. ". "Patients with simple eating disorders often experience severe depression in the later stages due to physical changes and poor interpersonal relationships." Chen Jun told a reporter from First Financial News, "There are two main causes of death for these people, one is suicide caused by depression, and the other is extreme malnutrition caused by anorexia, ultimately leading to death from malnutrition, infection, or heart failure." In addition, nausea and vomiting are common side effects of GLP-1 drugs. According to data from the US FDA, 44% of patients who receive weekly injections experience nausea and 30% experience vomiting. Some patients who cannot tolerate these side effects ultimately choose to withdraw. Regarding how physical discomfort affects a person's mental health, Chen Jun said, "There are mainly two factors. On the one hand, the side effects of nausea and vomiting can disrupt the stability of the body's internal environment, and on the other hand, psychological factors can also form a stressor." Chen Jun said that in daily outpatient visits, there are also some weight loss patients who seek psychological advice, but the overall proportion is not high. "We should still advocate scientific weight loss instead of blindly taking weight loss pills," he to
